Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: GLP-1 RA Group in Adults with type 2 diabetes - JSON Representation

Raw json | Download

{
  "resourceType" : "Group",
  "id" : "236948",
  "meta" : {
    "versionId" : "64",
    "lastUpdated" : "2024-12-16T14:20:03.936Z",
    "profile" : [
      🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-group"
    ]
  },
  "text" : {
    "status" : "empty",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/artifact-author",
      "valueContactDetail" : {
        "name" : "Computable Publishing®: MAGIC-to-FEvIR Converter"
      }
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact",
      "valueRelatedArtifact" : {
        "type" : "part-of",
        "resourceReference" : {
          "type" : "Composition",
          "identifier" : {
            "type" : {
              "text" : "FEvIR Linking Identifier"
            },
            "system" : "https://fevir.net/FLI",
            "value" : "MAGIC-5288-j1Wqrn-conversion-report",
            "assigner" : {
              "display" : "Computable Publishing LLC"
            }
          },
          "display" : "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"
        }
      }
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact",
      "valueRelatedArtifact" : {
        "type" : "cite-as",
        "citation" : "GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Group Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236948. Revised 2024-12-14. Available at: https://fevir.net/resources/Group/236948. Computable resource at: https://fevir.net/resources/Group/236948#json."
      }
    }
  ],
  "url" : "https://fevir.net/resources/Group/236948",
  "identifier" : [
    {
      "type" : {
        "coding" : [
          {
            "system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code" : "ACSN",
            "display" : "Accession ID"
          }
        ],
        "text" : "FEvIR Object Identifier"
      },
      "system" : "urn:ietf:rfc:3986",
      "value" : "https://fevir.net/FOI/236948",
      "assigner" : {
        "display" : "Computable Publishing LLC"
      }
    },
    {
      "type" : {
        "text" : "FEvIR Linking Identifier"
      },
      "system" : "https://fevir.net/FLI",
      "value" : "MAGIC-5288-j1Wqrn-comparator-group-MAGIC-5288-j1Wqrn-comparator-85394-C-85798",
      "assigner" : {
        "display" : "Computable Publishing LLC"
      }
    }
  ],
  "title" : "GLP-1 RA Group in Adults with type 2 diabetes",
  "status" : "active",
  "publisher" : "Computable Publishing LLC",
  "contact" : [
    {
      "telecom" : [
        {
          "system" : "email",
          "value" : "support@computablepublishing.com"
        }
      ]
    }
  ],
  "description" : "Glucagon-Like Peptide-1 (GLP-1) receptor agonists",
  "useContext" : [
    {
      "code" : {
        "system" : "https://fevir.net/resources/CodeSystem/179423",
        "code" : "evidence-communication",
        "display" : "Evidence Communication"
      },
      "valueCodeableConcept" : {
        "coding" : [
          {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "ComparatorGroup",
            "display" : "ComparatorGroup"
          }
        ]
      }
    }
  ],
  "copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "type" : "person",
  "membership" : "enumerated",
  "combinationMethod" : "all-of",
  "characteristic" : [
    {
      "code" : {
        "text" : "Member of"
      },
      "valueReference" : {
        🔗 "reference" : "Group/236947",
        "type" : "Group",
        "identifier" : {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "MAGIC-5288-j1Wqrn-population-group-85394-85798",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        },
        "display" : "Adults with type 2 diabetes and CVD and CKD"
      },
      "exclude" : false,
      "description" : "inclusion in Adults with type 2 diabetes"
    },
    {
      "code" : {
        "text" : "Exposed to"
      },
      "valueReference" : {
        🔗 "reference" : "Group/236776",
        "type" : "Group",
        "identifier" : {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "MAGIC-5288-j1Wqrn-comparator-85394-C-85798",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        },
        "display" : "Glucagon-Like Peptide-1 (GLP-1) receptor agonists"
      },
      "exclude" : false,
      "description" : "received GLP-1 RA"
    }
  ]
}